Sreeneeranj Kasichayanula

Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

Ralph A. DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula et al. · Diabetes Care · 2013 · 288 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

Robert R. Henry, Julio Rosenstock, Steven V. Edelman et al. · Diabetes Care · 2014 · 237 citations

Medicine, Pharmacology, Pharmacotherapy +15

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

Mary T. Obermeier, Ming Yao, Ashish Khanna et al. · Drug Metabolism and Disposition · 2009 · 181 citations

Medicine, Pharmacokinetics, Pharmacology +17

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

L. Zhang, Yingqing Feng, James F. List et al. · Diabetes Obesity and Metabolism · 2010 · 170 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

Sreeneeranj Kasichayanula, Xiaoni Liu, Melanie Pe Benito et al. · British Journal of Clinical Pharmacology · 2012 · 119 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17